Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator
Headquarters: Boston, MA, United States of America
Website: http://www.carb-x.org
Year Founded: 2016
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jul 20, 2023
Market Access
U.K. proposes model to value any antimicrobial as a subscription
Getting other countries to adopt similar strategies will be key to stimulating antibiotics development, says John Rex
BioCentury | Jul 5, 2022
Product Development
Fresh funding helps CARB-X home in on first-in-class strategies
Partnership kick-starts AMR innovation, but progress on U.S. pull incentives awaits Congressional action
BioCentury | May 31, 2022
Deals
GSK adds clinical vaccine, multi-antigen platform via $2.1B Affinivax buy
Deal rewards investors who backed company that was initially met by VCs’ skepticism of its M&A prospects
BioCentury | May 18, 2022
Finance
Series B builds Locus’ spending power for business development
With $35M financing, Locus is searching for expansion opportunities for its CRISPR and bacteriophage platforms
BioCentury | May 12, 2021
Deals
May 11 Quick Takes: $830M for tumor profiler Caris; plus Nuvalent’s $135M series B, Ginkgo’s $2.5B SPAC and updates from Adaptive, LianBio-Nanobiotix, Phico, Laevoroc
Sixth Street has made its third investment in molecular profiling company Caris Life Sciences Inc., leading a $830 million round at a postmoney valuation of $7.8 billion. The investment comes less
BioCentury | Feb 2, 2021
Finance
Prophylactic antibacterials backed by CARB-X: Data Byte
Since its 2016 launch, CARB-X has awarded $249.1 million across 67 therapeutics, vaccines and rapid diagnostic programs against the most serious drug-resistant bacteria identified by the WHO and CDC.
BioCentury | Jul 10, 2020
Politics, Policy & Law
Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms
AMR Action Fund pushing antibiotic development but pull mechanisms needed urgently
BioCentury | Jul 10, 2020
Politics, Policy & Law
Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund
Q&A on the AMR Fund with Thomas Cueni, director general of IFPMA
BioCentury | Jul 9, 2020
Finance
July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn
BioCentury | Jun 19, 2019
Company News
June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more
Items per page:
1 - 10 of 35